NovoCure Limited
Key Metrics
- Previous Close
- $11.14
- 52-Week Range
- $9.82 – $21.45
- Market Cap
- $1.25B
- P/E (TTM)
- —
- EPS (TTM)
- -1.06
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.44
- PEG Ratio
- —
- Return on Equity
- -35.19%
- Return on Assets
- -6.79%
- Gross Margin
- 77.25%
- Operating Margin
- -16.41%
- Profit Margin
- -16.78%
- Current Ratio
- 2.49
- Debt/Equity
- 0.66
- Total Debt
- $231.55M
- Free Cash Flow
- $9.00M
- Revenue Growth
- 15.70%
- Earnings Growth
- —
- Enterprise Value
- $1.02B
Market Snapshot
About
NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) therapy, a novel cancer treatment that uses electric fields to disrupt cell division in tumors. The flagship product Optune is FDA-approved for glioblastoma and mesothelioma. NovoCure is conducting clinical trials across multiple solid tumor types including brain, lung, ovarian, and pancreatic cancers.